"Adverse Drug Reaction in Uterine Cancer: A Reviewof Therapeutic Challenges"

Uterine cancer, mainly endometrial carcinoma, poses an increasing clinical challenge because of its surging incidence and complicated treatment options. Treatment protocols—such as chemotherapy, radiation therapy, and targeted immunotherapy—have greatly enhanced survival rates but often come with considerable side effects. In individuals treated with lenvatinib and pembrolizumab, frequent adverse effects consist of hypothyroidism, hypertension, fatigue, diarrhea, and musculoskeletal issues, with grade 3–4 incidents like significant fatigue and weight loss appearing in more than 10% of patients. Radiotherapy, especially for high-risk patients, is linked to gastrointestinal and genitourinary toxicities, and its adverse effects are worsened by factors like age, obesity, lymphovascular space invasion (LVSI), and postponement of treatment initiation2. Additionally, stereotactic pelvic adjuvant radiation therapy has demonstrated acute gastrointestinal and genitourinary toxicities, affecting patients' quality of life even with its therapeutic effectiveness. To effectively handle these negative reactions, proactive monitoring, educating patients, and strategic dose adjustments are needed to weigh treatment advantages against tolerability